Want to see TSE:MSCL full AI Analyst Report?

Satellos Bioscience (MSCL) Price & Analysis

38 Followers

MSCL Stock Chart & Stats

C$11.91

C$0.01(1.16%)

At close: Jan 08 4:00 PM EST

C$11.91

C$0.01(1.16%)

Day’s Range― - ―

52-Week RangeC$6.36 - C$18.98

Previous CloseN/A

Volume29.01K

Average Volume (3M)178.54K

Market Cap

C$212.48M

Enterprise ValueC$41.10M

Total Cash (Recent Filing)C$69.96M

Total Debt (Recent Filing)C$0.00

Price to Earnings (P/E)―

Beta1.45

Next Earnings

Aug 31, 2026

EPS Estimate

-0.71

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.96

Shares Outstanding20,831,190

10 Day Avg. Volume239,110

30 Day Avg. Volume178,539

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)3.04

Price to Sales (P/S)0.00

P/FCF Ratio-3.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$30.55

Price Target Upside156.49% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-2.88

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free capital structure materially lowers solvency risk and interest burdens, giving management durable flexibility to fund R&D via equity, partnerships, or grants. This reduces near-term bankruptcy risk and preserves strategic optionality while the pipeline matures.

Focused Rare-disease PipelineConcentrating on skeletal muscle diseases, including Duchenne, targets high unmet medical need and potential orphan-drug incentives. This focused expertise can drive partnership interest, premium pricing potential, and long-term revenue if clinical success is achieved, creating durable upside.

Lean Operating StructureA small headcount indicates a lean cost base that can stretch cash runway and reduce fixed overhead in a pre-revenue phase. This structural efficiency supports prolonged R&D activity per funding round and enables flexible outsourcing of development tasks to CROs and partners.

Bears Say

Pre-revenue With Widening LossesBeing pre-revenue with a large TTM net loss means the company lacks internal cash generation to self-fund development. Sustained negative earnings increase execution risk: clinical setbacks or delays necessitate external capital, raising dilution risk and constraining long-term strategic choices.

Persistent Negative Free Cash FlowConsistent negative operating cash flow and large TTM FCF indicate ongoing cash burn funding operations rather than value generation. This structural cash deficit forces repeated financings or partnerships, which can be dilutive, time-consuming, and may disrupt program timelines if markets tighten.

Negative Returns And Volatile EquityVery negative ROE and volatile equity reflect accumulated losses and significant capital activity, eroding shareholder value over time. This pattern makes future fundraising more expensive or dilutive, and signals governance and capital-allocation challenges that can impede long-term investor confidence.

Satellos Bioscience News

Satellos announces Fast Track designation for SAT-3247

Satellos (MSLE) announced that the FDA has granted Fast Track designation to SAT-3247 for the treatment of Duchenne....

5d ago

MSLE

Satellos Wins FDA Fast Track Status for Duchenne Drug SAT-3247

Satellos Bioscience ( ($TSE:MSCL) ) has issued an announcement. On June 29, 2026, Satellos announced that the U.S....

5d ago

MSLE

Satellos to Present SAT-3247 Clinical Updates at ICNMD 2026

Satellos Bioscience ( ($TSE:MSCL) ) just unveiled an announcement. On June 25, 2026, Satellos Bioscience Inc. reported that...

9d ago

MSLE

Satellos Bioscience Shareholders Back Board Slate and Auditor at June 17 Annual Meeting

Satellos Bioscience ( ($TSE:MSCL) ) has issued an announcement. On June 17, 2026, Satellos Bioscience Inc. reported the...

16d ago

MSLE

Satellos Bioscience Shareholders Back Board Slate and Auditor at June 17 AGM

The latest announcement is out from Satellos Bioscience ( ($TSE:MSCL) ). Satellos Bioscience reported the results of its...

17d ago

MSLE

Satellos Bioscience to Highlight Neuromuscular Pipeline at June Investor Conferences

An update from Satellos Bioscience ( ($TSE:MSCL) ) is now available. On May 27, 2026, Satellos Bioscience announced...

1M ago

MSLE

Satellos resumed with a Speculative Buy at Canaccord

Canaccord analyst Tania Armstrong-Whitworth resumed coverage of Satellos (MSLE) with a Speculative Buy rating and C$19 price target...

1M ago

MSLE

Satellos Bioscience Sets June 17, 2026 Virtual Annual Shareholder Meeting

Satellos Bioscience ( ($TSE:MSCL) ) has provided an announcement. Satellos Bioscience has called its annual general meeting of...

2M ago

MSLE

Satellos reports Q1 EPS (53c), consensus (59c)

“The first quarter of 2026 was a productive time for Satellos (MSLE). We raised $57M, providing runway to...

2M ago

MSLE

Satellos Bioscience Posts Wider Q1 2026 Loss but Strengthens Balance Sheet

Satellos Bioscience ( ($TSE:MSCL) ) just unveiled an announcement. Satellos Bioscience filed its Form 6-K for May 2026,...

2M ago

MSLE

Satellos initiated with a Buy at Guggenheim

Guggenheim initiated coverage of Satellos (MSLE) with a Buy rating and $23 price target Published first on TheFly...

2M ago

MSLE

Satellos Bioscience to Showcase DMD Program at April Bloom Burton Healthcare Investor Conference

Satellos Bioscience ( ($TSE:MSCL) ) has issued an announcement. Satellos Bioscience Inc., a clinical-stage biotech developer of small...

3M ago

MSLE

Satellos management to meet with Oppenheimer

Dinner Meeting to be held on April 16 hosted by Oppenheimer. Published first on TheFly – the ultimate...

3M ago

MSLE

3 Best Stocks to Buy Now, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

3M ago

FUTU

KTOS

MSCL FAQ

What was Satellos Bioscience’s price range in the past 12 months?

Satellos Bioscience lowest stock price was C$6.36 and its highest was C$18.98 in the past 12 months.

What is Satellos Bioscience’s market cap?

Satellos Bioscience’s market cap is C$212.48M.

When is Satellos Bioscience’s upcoming earnings report date?

Satellos Bioscience’s upcoming earnings report date is Aug 31, 2026 which is in 58 days.

How were Satellos Bioscience’s earnings last quarter?

Satellos Bioscience released its earnings results on May 15, 2026. The company reported -C$0.729 earnings per share for the quarter, missing the consensus estimate of -C$0.675 by -C$0.054.

Is Satellos Bioscience overvalued?

According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Satellos Bioscience pay dividends?

Satellos Bioscience does not currently pay dividends.

What is Satellos Bioscience’s EPS estimate?

Satellos Bioscience’s EPS estimate is -0.71.

How many shares outstanding does Satellos Bioscience have?

Satellos Bioscience has 20,831,190 shares outstanding.

What happened to Satellos Bioscience’s price movement after its last earnings report?

Satellos Bioscience reported an EPS of -C$0.729 in its last earnings report, missing expectations of -C$0.675. Following the earnings report the stock price went down -0.201%.

Which hedge fund is a major shareholder of Satellos Bioscience?

Currently, no hedge funds are holding shares in TSE:MSCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Satellos Bioscience Stock Smart Score

Outperform

Fundamentals

Return on Equity

-51.42%

Trailing 12-Months

Asset Growth

69.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Satellos Bioscience

Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.

Satellos Bioscience (MSCL) Earnings & Revenues

Historic Earnings Reports

MSCL Stock 12 Month Forecast

Average Price Target

C$30.55

▲(156.49% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"C$5","18":"C$18","31":"C$31","44":"C$44","57":"C$57"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56.910176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$56.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.547782719999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$30.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.6502984,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$15.65</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,18,31,44,57],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.57,13.211552000000001,16.853104000000002,20.494656,24.136208,27.77776,31.419311999999998,35.060863999999995,38.702416,42.343968,45.98552,49.627072,53.268623999999996,{"y":56.910176,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.57,11.183675593846154,12.797351187692307,14.41102678153846,16.024702375384614,17.638377969230767,19.25205356307692,20.865729156923074,22.479404750769227,24.09308034461538,25.706755938461537,27.32043153230769,28.934107126153844,{"y":30.547782719999997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.57,10.037715261538462,10.505430523076923,10.973145784615385,11.440861046153847,11.908576307692307,12.37629156923077,12.844006830769231,13.311722092307694,13.779437353846154,14.247152615384616,14.714867876923076,15.182583138461538,{"y":15.6502984,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.519,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.92,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.99,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.62,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >